Foreword
Donald J. Tindall
page vii
Full Text | Full-Text PDF (45 KB)

Executive Summary of the National Cancer Institute Workshop: Highlights and recommendations
Ronald Lieberman, William G Nelson, Wael A Sakr, Frank L Meyskens, Eric A Klein, George Wilding, Alan W Partin, J.Jack Lee, Scott M Lippman
pages 4-27
Abstract | Full Text | Full-Text PDF (1012 KB)

Similarities of prostate and breast cancer: Evolution, diet, and estrogens
Donald S Coffey
pages 31-38
Abstract | Full Text | Full-Text PDF (246 KB)

Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer
Gary J Kelloff, Ronald Lieberman, Vernon E Steele, Charles W Boone, Ronald A Lubet, Levy Kopelovich, Winfred A Malone, James A Crowell, Howard R Higley, Caroline C Sigman
pages 46-51
Abstract | Full Text | Full-Text PDF (136 KB)

Prostate cancer prevention agent development: Criteria and pipeline for candidate chemoprevention agents
William G Nelson, George Wilding
pages 56-63
Abstract | Full Text | Full-Text PDF (150 KB)

Selective estrogen receptor modulators for the chemoprevention of prostate cancer
Mitchell S Steiner, Sharan Raghow, Blake L Neubauer
pages 68-72
Abstract | Full Text | Full-Text PDF (139 KB)

Tyrosine kinase inhibitors and signal transduction modulators: Rationale and current status as chemopreventive agents for prostate cancer
Raymond C Bergan, Doyle H Waggle, Stephen K Carter, Ivan Horak, William Slichenmyer, Michael Meyers
pages 77-80
Abstract | Full Text | Full-Text PDF (152 KB)

Other novel agents: Rationale and current status as chemopreventive agents
Anthony W Tolcher, Ann Kennedy, Robert J Padley, Noreen Majeed, Michael Pollak, Philip W Kantoff
pages 86-89
Abstract | Full Text | Full-Text PDF (114 KB)

New biologicals for prostate cancer prevention: Genes, vaccines, and immune-based interventions
Allan J Pantuck, Amnon Zisman, Daniel Henderson, Deborah Wilson, Alain Schreiber, Arie Belldegrun
pages 95-99
Abstract | Full Text | Full-Text PDF (116 KB)

New concepts in the pathology of prostatic epithelial carcinogenesis
Angelo M De Marzo, Mathew J Putzi, William G Nelson
pages 103-114
Abstract | Full Text | Full-Text PDF (315 KB)

Imaging and prostate cancer chemoprevention: Current diagnosis and future directions
Peter J Littrup
pages 121-123
Abstract | Full Text | Full-Text PDF (622 KB)

Computer-assisted image analysis–derived intermediate endpoints
Charles W. Boone, Ronald Lieberman, Thomas Mairinger, Branko Palcic, James Bacus, Peter Bartels
pages 129-131
Abstract | Full Text | Full-Text PDF (125 KB)

Oxidative stress in chemoprevention trials
Theodore L. DeWeese, Andrew M. Hruszkewycz, Lawrence J. Marnett
pages 137-140
Abstract | Full Text | Full-Text PDF (111 KB)

Angiogenesis as a potential biomarker in prostate cancer chemoprevention trials
Iqbal Unnisa Ali, Donald R Senger, Lois E.H Smith
pages 143-147
Abstract | Full Text | Full-Text PDF (689 KB)

Sequence databases and microarrays as tools for identifying prostate cancer biomarkers
Lynette H Grouse, Peter J Munson, Peter S Nelson
pages 154-159
Abstract | Full Text | Full-Text PDF (858 KB)

Standardization, analytical validation, and quality control of intermediate endpoint biomarkers
Robert W Veltri, M.Craig Miller, Gang An
pages 164-170
Abstract | Full Text | Full-Text PDF (401 KB)

Prostate-specific antigen–enhanced testing and risk stratification for chemoprevention trials1
Judd W Moul
pages 174-177
Abstract | Full Text | Full-Text PDF (122 KB)

A randomized, controlled chemoprevention trial of selenium in familial prostate cancer: Rationale, recruitment, and design issues
Anthony J Costello
pages 182-184
Abstract | Full Text | Full-Text PDF (111 KB)

Chemoprevention for prostatic carcinoma: The role of flutamide in patients with prostatic intraepithelial neoplasia
Steven R. Alberts, Michael L. Blute
pages 188-190
Abstract | Full Text | Full-Text PDF (95 KB)

Preprostatectomy: A clinical model to study stromal-epithelial interactions
Wlodek Lopaczynski, Andrew M Hruszkewycz, Ronald Lieberman
pages 194-199
Abstract | Full Text | Full-Text PDF (218 KB)

Chemoprevention trials in men with prostate-specific antigen failure or at high risk for recurrence after radical prostatectomy: Application to efficacy assessment of soy protein
Maarten C Bosland, Ikuko Kato, Jonathan Melamed, Samir Taneja, Herbert Lepor, Pablo Torre, Paul Walden, Anne Zeleniuch-Jacquotte, L.H Lumey
pages 202-204
Abstract | Full Text | Full-Text PDF (100 KB)

Trial endpoints for drug approval in oncology: Chemoprevention1
Julie Beitz
pages 213-215
Abstract | Full Text | Full-Text PDF (91 KB)

Bayesian monitoring of a phase 2 chemoprevention trial in high-risk cohorts for prostate cancer
Heidi L Weiss, Donald A Urban, William E Grizzle, Kathleen A Cronin, Laurence S Freedman, Gary J Kelloff, Ronald Lieberman
pages 220-223
Abstract | Full Text | Full-Text PDF (123 KB)

The Prostate Cancer Prevention Trial: Current status and lessons learned
Ian M Thompson, Margaret Kouril, Eric A. Klein, Charles A Coltman, Anne Ryan, Phyllis Goodman
pages 230-234
Abstract | Full Text | Full-Text PDF (180 KB)